Thalidomide: 7 days
Immunomodulator therapy (IMiD e.g. lenalidomide or thalidomide) -1 week
History of allergy to mannitol or prior hypersensitivity to thalidomide, lenalidomide or pomalidomide
Prior treatment with lenalidomide; patients previously treated with thalidomide who discontinued treatment for reasons aside from an adverse reaction to thalidomide are permitted
Known hypersensitivity to thalidomide or lenalidomide
Patients who experienced thromboembolic events while on full anticoagulation during prior therapy with lenalidomide or thalidomide.
Any prior treatment with pomalidomide. Subjects who have prior treatment with other immunomodulatory compounds (thalidomide, lenalidomide) ARE eligible if they meet all other eligibility criteria and did not have allergic reactions or other \significant toxicity\ per Investigator discretion associated with lenalidomide or thalidomide use.
Lenalidomide, thalidomide or other immunomodulatory drugs (IMiDs)
Prior therapy with elotuzumab or any immunomodulatory drug (IMiD) (including pomalidomide), except for prior thalidomide or lenalidomide (as defined in inclusion criteria)
History of grade 4 rash associated with thalidomide treatment
Known hypersensitivity to lenalidomide or thalidomide, ibrutinib, rituximab, etoposide, vincristine,\r\ndoxorubicin, cyclophosphamide, or prednisone
History of hypersensitivity of lenalidomide or thalidomide
Patients with history of previous immunomodulatory therapy (not including lenalidomide or thalidomide)
Lenalidomide, thalidomide and pomalidomide
Known hypersensitivity to thalidomide or lenalidomide
Known hypersensitivity to thalidomide, lenalidomide or ipilimumab
Known hypersensitivity or desquamating rash to either thalidomide or lenalidomide
Known hypersensitivity to thalidomide or lenalidomide
Subject has known hypersensitivity to dexamethasone, clarithromycin, lenalidomide, or thalidomide
Hypersensitivity to thalidomide, lenalidomide, pomalidomide, bortezomib, or dexamethasone (such as Stevens-Johnson syndrome); rash to immunomodulatory drug that can be medically managed is allowable
History of erythema multiforme or severe hypersensitivity to prior IMiD’s such as thalidomide and lenalidomide
Had rash ? Grade 3 during prior thalidomide, lenalidomide, or pomalidomide therapy
Has a history of anaphylaxis or hypersensitivity to thalidomide, lenalidomide, POM, or dex
Prior thalidomide is allowed, however, patients must not have prior >= grade-3 allergic reactions to thalidomide
History of erythema multiforme, Grade >= 3 rash, or blistering following prior treatment with immunomodulatory derivatives such as thalidomide and lenalidomide
Hypersensitivity to thalidomide, lenalidomide, pomalidomide, or dexamethasone
For MM-2 cohort only: Hypersensitivity (eg, Rash Grade 3 or 4) to thalidomide, lenalidomide, or dexamethasone (MM-2b).
Hypersensitivity to IMiDs (thalidomide or lenalidomide) defined as any hypersensitivity reaction leading to stop IMiDs within the 2 first cycles or toxicity, which does meet intolerance definition.
Arm A only: ImiDs (eg, lenalidomide, thalidomide);
Prior therapy with thalidomide in combination with ruxolitinib
Known hypersensitivity to thalidomide or lenalidomide
Patients with a prior history of serious allergic reactions associated with thalidomide or lenalidomide
Patients who have received pomalidomide in the past are not eligible; patients who have prior treatment with other immunomodulatory drugs (IMiDs) (thalidomide, lenalidomide) ARE eligible if they meet all other eligibility criteria and did not have \significant toxicity\ associated with lenalidomide or thalidomide use; a “significant” toxicity will be defined as one that required a dose reduction or discontinuation due to toxicity; please discuss any questions with the PI
Known hypersensitivity to thalidomide or lenalidomide
Known hypersensitivity to thalidomide or lenalidomide
Patients who have received hydroxyurea alone or have received non-cytotoxic therapies previously for treatment of MDS or myeloproliferative neoplasm (MPN) (e.g. azacitidine, decitabine, histone deacetylase inhibitors, tyrosine kinase inhibitors, hematopoietic growth factors, interferon, lenalidomide, thalidomide) will be eligible for this trial as long as immunomodulatory drugs (e.g. lenalidomide, thalidomide) have not been used in the past 3 months
Hypersensitivity to thalidomide, lenalidomide, or dexamethasone (such as Steven Johnson Syndrome). Hypersensitivity, such as rash, that can be medically managed is allowable
Hypersensitivity to previous lenalidomide or thalidomide
Patients with a prior history of grade 4 rash associated with thalidomide treatment
Hypersensitivity to thalidomide, lenalidomide or pomalidomide
Known hypersensitivity to thalidomide or lenalidomide (if applicable)
Known hypersensitivity to thalidomide or lenalidomide.
Known hypersensitivity to thalidomide or lenalidomide
Known hypersensitivity to thalidomide or lenalidomide.
Prior therapy with thalidomide and lenalidomide is allowed
Must have received at least one (1) prior line of systemic treatment that has included either lenalidomide or thalidomide.
Known hypersensitivity to thalidomide, lenalidomide, azacitidine, or mannitol
Known hypersensitivity to thalidomide or lenalidomide (if applicable)
Grade 4 rash due to prior thalidomide treatment
Have known hypersensitivity to thalidomide or lenalidomide
Patients with known hypersensitivity to thalidomide or lenalidomide or pomalidomide
Known hypersensitivity to thalidomide or lenalidomide
Patients who were previously exposed and who developed severe adverse events, hypersensitivity or desquamating rash to either thalidomide or lenalidomide
History of hypersensitivity to IMiDs® (lenalidomide, pomalidomide, thalidomide).
Known hypersensitivity to thalidomide or lenalidomide (if applicable)
Known hypersensitivity to thalidomide or Revlimid (if applicable)
Known hypersensitivity to thalidomide or lenalidomide
Known history of resistance to thalidomide
Lenalidomide, thalidomide and pomalidomide
Subjects must have received prior treatment with bortezomib, and either thalidomide or lenalidomide
Known hypersensitivity to lenalidomide or thalidomide
Hypersensitivity to thalidomide, lenalidomide, or dexamethasone
Prior Therapy with thalidomide, lenalidomide or pomalidomide
Prior therapy with histone deacetylase (HDAC) inhibitors or immunomodulatory drugs (IMDs) (lenalidomide or thalidomide)
Known hypersensitivity to thalidomide or lenalidomide (if applicable)
Known hypersensitivity to thalidomide or lenalidomide
Known sensitivity to lenalidomide or other thalidomide derivatives